The US FDA would be required to set up an internal council to ensure consistent application of the accelerated approval pathway under bipartisan user fee legislation introduced in the Senate on 27 May.
The Food and Drug Administration Safety and Landmark Advancements Act (FDASLA), introduced by Health, Education, Labor and Pensions committee...







